Bring out the circumstances in 2005 which forced amendment to section 3(d) in the Indian Patent Law, 1970. Discuss how it has been utilized by Supreme court in its judgment rejecting Novartis patent application for “Glivec”. Discuss briefly the pros and cons of the decision.

Introduction

The Indian Patent Act, 1970, was amended in 2005 to comply with the TRIPS Agreement under the WTO framework. However, concerns over evergreening of patents—a practice where minor modifications to existing drugs are patented to extend monopoly—led to the introduction of Section 3(d). This provision aimed to prevent frivolous patents and ensure access to affordable medicines, a critical issue for a country like India with a large population dependent on generic drugs.

Value Addition Block — Key Context

Key Features of Section 3(d):

• Prohibits patents for new forms of known substances unless they demonstrate enhanced efficacy.
• Aimed at balancing innovation incentives with public health priorities.

Circumstances Leading to the 2005 Amendment

• TRIPS Compliance (1995): India, as a WTO member, was required to align its patent laws with TRIPS, mandating product patents for pharmaceuticals.
• Concerns over Evergreening: Multinational pharmaceutical companies sought patents for minor modifications, threatening the availability of affordable generics.
• Public Health Advocacy: Civil society groups and health organizations, such as MSF (Médecins Sans Frontières), highlighted the potential impact on access to life-saving drugs.
• Judicial and Legislative Push: The need to safeguard public health led to the inclusion of Section 3(d) in the Patents (Amendment) Act, 2005, to prevent abuse of patent rights.

Supreme Court Judgment on Novartis' "Glivec" Patent Application

The Supreme Court of India (2013) rejected Novartis' patent application for the anti-cancer drug Glivec under Section 3(d). Key aspects of the judgment include:

• Reason for Rejection:

  • Novartis sought a patent for a beta-crystalline form of imatinib mesylate, claiming improved properties.
  • The Court ruled that the modification did not demonstrate significant enhancement in therapeutic efficacy, as required under Section 3(d).

• Significance of the Judgment:

  • Reinforced the anti-evergreening intent of Section 3(d).
  • Upheld India's commitment to public health by ensuring affordable access to generic versions of Glivec.
  • Set a global precedent for balancing intellectual property rights with public interest.

Pros and Cons of the Decision

Pros

• Affordable Medicines: Enabled the production of generic Glivec, reducing costs from ₹1.2 lakh/month to ₹8,000/month, benefiting cancer patients.
• Public Health Priority: Strengthened India's position as the "pharmacy of the world" by ensuring access to affordable generics.
• Judicial Clarity: Provided a clear interpretation of efficacy under Section 3(d), discouraging frivolous patent claims.
• Global Impact: Inspired other developing nations to adopt similar measures to protect public health.

Cons

• Innovation Concerns: Critics argue that stringent patent laws may discourage pharmaceutical R&D investment in India.
• Ambiguity in Efficacy Standards: The subjective interpretation of "enhanced efficacy" could lead to inconsistent application of Section 3(d).
• Global Backlash: The decision faced criticism from multinational pharmaceutical companies and some developed nations, citing non-compliance with TRIPS.

Conclusion

The Novartis judgment exemplifies India's commitment to balancing intellectual property rights with public health imperatives, aligning with DPSP (Article 47) to improve public health. While it safeguards affordable access to medicines, India must also foster an ecosystem that encourages pharmaceutical innovation to address emerging health challenges.